Special Issue

Interference of Bacterial Signaling as a New Strategy for Treatment of AMR Pathogens

Message from the Guest Editor

The increase and spread of AMR (antimicrobial resistance) pathogens with a shortage of new antimicrobial agents are critical issues. Bacteria use particular signal molecules when they encounter environmental changes or contact with other bacterial members, then alter their gene expression. This manner termed "bacterial signaling" has been observed in many species including animal and plant pathogens. There is increasing evidence that it is closely associated with bacterial virulence, and characterized as virulence determinants to establish infections. Thus, bacterial signaling is proposed as a potential target for the development of antimicrobial agents. This Issue will provide updates on topics related to bacterial signaling interference and conquering refractory AMR infections. We invite manuscripts on studies that include the following topics: Chemical compounds, proteins, or nucleic acids targetting bacterial signaling and their molecular mechanisms; Innovative chemotherapy applications and the use of inhibitors of bacterialsignaling (such as combination chemotherapy) Keywords: antimicrobial resistance; bacterial signal; quorum sensing; biofilm; virulence

Guest Editor

Dr. Hidetada Hirakawa

Department of Bacteriology, Gunma University Graduate School of Medicine, Maebashi, Japan

Deadline for manuscript submissions

closed (31 July 2021)



an Open Access Journal by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



mdpi.com/si/38033

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

mdpi.com/journal/ antibiotics





an Open Access Journal by MDPI

Impact Factor 4.6 CiteScore 8.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery. use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. Antibiotics is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon

School of Chemistry and Molecular Bioscience, University of Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

